{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-013509","form_type":"8-K","ticker":"OTLK","cik":"0001649989","company_name":"Outlook Therapeutics, Inc.","filed_at":"2025-02-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.307572+00:00","generated_at":"2026-05-26T21:25:57.625157+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Outlook Q1: GAAP EPS $0.72 (fair value gains), adj EPS -$0.89; BLA resubmission on track","bullets":["GAAP net income $17.4M ($0.72/sh) vs net loss $11.2M; adj net loss $21.6M ($0.89/sh) vs $10.1M ($0.78 loss) prior year.","BLA resubmission for ONS-5010 (bevacizumab-vikg) targeted for Q1 CY2025; potential FDA approval in Q3 CY2025.","First commercial launches of LYTENAVA in Germany and UK planned for Q2 CY2025; collaboration with Cencora announced.","NORSE EIGHT trial missed primary non-inferiority endpoint at week 8; 12-week analysis met non-inferiority margin."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-013509","json":"https://secwatch.observer/filing/0001104659-25-013509.json","markdown":"https://secwatch.observer/filing/0001104659-25-013509.md","text":"https://secwatch.observer/filing/0001104659-25-013509.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1649989/000110465925013509/0001104659-25-013509-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1649989/000110465925013509/tm256608d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T21:25:57.625157+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}